Organovo Highlights FXR314 Combination Therapy Potential and

SAN DIEGO, Nov. 08, 2023 -- Organovo Holdings, Inc. , a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease , based on...

Related Keywords

United States , Keith Murphy , Globenewswire Inc , Organovo Holdings Inc , Nasdaq , Organovo Inc , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,